Universe Pharmaceuticals, Inc. is a pharmaceutical company. The company is headquartered in Ji'An, Jiangxi and currently employs 216 full-time employees. The company went IPO on 2021-03-23. The Company’s products include chronic condition treatments and cold and flu medicines. The chronic condition treatments primarily include Guben Yanling Pill, Shenrong Weisheng Pill, Quanlu Pill, Yangxue Danggui Syrup, Wuzi Yanzong Oral Liquid, Fengtong Medicinal Liquor, Shenrong Medicinal Liquor, Qishe Medicinal Liquor, Fengshitong Medicinal Liquor, and Shiquan Dabu Medicinal Liquor. The cold and flu medicines primarily include Paracetamol Granule for children, Isatis Root Granule and Qiangli Pipa Syrup. The firm is also engaged in the sales of biomedical drugs medical instruments, Traditional Chinese Medicine Pieces (TCMPs), and dietary supplements manufactured by third-party pharmaceutical companies.
The most recent EPS for Universe Pharmaceuticals Inc is $, expectations of $.
How did Universe Pharmaceuticals Inc UPC's revenue perform in the last quarter?
Universe Pharmaceuticals Inc revenue for the last quarter is $
What is the revenue estimate for Universe Pharmaceuticals Inc?
According to of Wall street analyst, the revenue estimate of Universe Pharmaceuticals Inc range from $ to $
What's the earning quality score for Universe Pharmaceuticals Inc?
Universe Pharmaceuticals Inc has a earning quality score of B+/52.59882. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Universe Pharmaceuticals Inc report earnings?
Universe Pharmaceuticals Inc next earnings report is expected in 2026-04-29
What are Universe Pharmaceuticals Inc's expected earnings?
Universe Pharmaceuticals Inc expected earnings is $, according to wall-street analysts.
Did Universe Pharmaceuticals Inc beat earnings expectations?
Universe Pharmaceuticals Inc recent earnings of $ expectations.